Safety profile of idursulfase administered at home in patients with mucopolysaccharidosis II enrolled in the Hunter Outcome Survey.

Saved in:
Bibliographic Details
Title: Safety profile of idursulfase administered at home in patients with mucopolysaccharidosis II enrolled in the Hunter Outcome Survey.
Authors: Burton BK; Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern University, Chicago, IL, USA., Guffon N; Reference Center for Inherited Metabolic Diseases, Hospices Civils de Lyon, Lyon, France., Roberts J; Saint Mary's Hospital, Manchester, UK., van der Ploeg AT; Center for Lysosomal and Metabolic Diseases, Erasmus MC University Medical Center, Rotterdam, Netherlands., Jones SA; Saint Mary's Hospital, Manchester, UK., Audi J; Takeda Pharmaceuticals International AG, Zürich, Switzerland., Botha J; Takeda Pharmaceuticals International AG, Zürich, Switzerland. Electronic address: jaco.botha@takeda.com., Whiteman DAH; Takeda Pharmaceutical Company Limited, Lexington, MA, USA., Giugliani R; Postgraduate Program in Genetics and Molecular Biology UFRGS, Medical Genetics Service HCPA, INAGEMP, DASA and Casa dos Raros, Porto Alegre, Brazil., Muenzer J; University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Source: Molecular genetics and metabolism [Mol Genet Metab] 2026 Mar; Vol. 147 (3), pp. 109734. Date of Electronic Publication: 2026 Jan 12.
Publication Type: Journal Article
Journal Info: Publisher: Academic Press Country of Publication: United States NLM ID: 9805456 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1096-7206 (Electronic) Linking ISSN: 10967192 NLM ISO Abbreviation: Mol Genet Metab Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1096-7206
DOI:10.1016/j.ymgme.2026.109734